Abstract
L-Glutamate is the major excitatory neurotransmitter in mammalian central nervous system, and excitatory amino acid transporters (EAATs) are essential for terminating synaptic excitation and for maintaining extracellular glutamate concentration below toxic levels. Although the structure of these channel-like proteins has not been yet reported, their membrane topology has been hypothesised based on biochemical and protein sequence analyses. In the case of an inadequate clearance from synaptic cleft and from the extrasynaptic space, glutamate behaves as a potent neurotoxin, and it may be related to several neurodegenerative pathologies including epilepsy, ischemia, amyotrophic lateral sclerosis, and Alzheimer disease. The recent boom of glutamate is demonstrated by the enormous amount of publications dealing with the function of glutamate, with its role on modulation of synaptic transmission throughout the brain, mainly focusing: i) on the structure of its receptors, ii) on molecular biology and pharmacology of Glu transporters, and iii) on the role of glutamate uptake and reversal uptake in several neuropathologies. This review will deal with the recent and most interesting published results on Glu transporters membrane topology, Glu transporters physiopathological role and Glu transporters medicinal chemistry, highlighting the guidelines for the development of potential neuroprotective agents targeting neuronal high-affinity sodium-dependent glutamate transporters.
Keywords: l-glutamake transporter, eaats, neurodegenerative disorder, neurotransmitter, glu, excitatory amino acid transporter
Current Pharmaceutical Design
Title: Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases
Volume: 9 Issue: 8
Author(s): Giuseppe Campiani, Caterina Fattorusso, Meri De Angelis, Bruno Catalanotti, Stefania Butini, Roberto Fattorusso, Isabella Fiorini, Vito Nacci and Ettore Novellino
Affiliation:
Keywords: l-glutamake transporter, eaats, neurodegenerative disorder, neurotransmitter, glu, excitatory amino acid transporter
Abstract: L-Glutamate is the major excitatory neurotransmitter in mammalian central nervous system, and excitatory amino acid transporters (EAATs) are essential for terminating synaptic excitation and for maintaining extracellular glutamate concentration below toxic levels. Although the structure of these channel-like proteins has not been yet reported, their membrane topology has been hypothesised based on biochemical and protein sequence analyses. In the case of an inadequate clearance from synaptic cleft and from the extrasynaptic space, glutamate behaves as a potent neurotoxin, and it may be related to several neurodegenerative pathologies including epilepsy, ischemia, amyotrophic lateral sclerosis, and Alzheimer disease. The recent boom of glutamate is demonstrated by the enormous amount of publications dealing with the function of glutamate, with its role on modulation of synaptic transmission throughout the brain, mainly focusing: i) on the structure of its receptors, ii) on molecular biology and pharmacology of Glu transporters, and iii) on the role of glutamate uptake and reversal uptake in several neuropathologies. This review will deal with the recent and most interesting published results on Glu transporters membrane topology, Glu transporters physiopathological role and Glu transporters medicinal chemistry, highlighting the guidelines for the development of potential neuroprotective agents targeting neuronal high-affinity sodium-dependent glutamate transporters.
Export Options
About this article
Cite this article as:
Campiani Giuseppe, Fattorusso Caterina, Angelis De Meri, Catalanotti Bruno, Butini Stefania, Fattorusso Roberto, Fiorini Isabella, Nacci Vito and Novellino Ettore, Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases, Current Pharmaceutical Design 2003; 9 (8) . https://dx.doi.org/10.2174/1381612033391261
DOI https://dx.doi.org/10.2174/1381612033391261 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier
Current Drug Metabolism Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Positron Emission Tomography and Brain Monoamine Neurotransmission - Entries for Study of Drug Interactions
Current Pharmaceutical Design Pharmacogenetic Approach to Treating Drug Dependence: Serotonin Transporter Gene (SLC6A4) Promoter Polymorphisms as Treatment Predictors in Jordanian Arabs
Current Pharmacogenomics and Personalized Medicine Mobilization and Redistribution of Default Mode Network from Resting State to Task State in Amnestic Mild Cognitive Impairment
Current Alzheimer Research Clinical Potential of Neuropeptide Y Receptor Ligands in the Treatment of Epilepsy
Current Topics in Medicinal Chemistry In Search of Novel AMPA Potentiators
Recent Patents on CNS Drug Discovery (Discontinued) Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology Revised Genetic Classification of Limb Girdle Muscular Dystrophies
Current Molecular Medicine Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy Phenolic Compounds as Antioxidants: Carbonic Anhydrase Isoenzymes Inhibitors
Mini-Reviews in Medicinal Chemistry Cefepime-Induced Neurotoxicity
Central Nervous System Agents in Medicinal Chemistry Immunogenicity, Immunopathogenicity, and Immunotolerance in One Graph
Anti-Cancer Agents in Medicinal Chemistry Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Gut Microbiota Regulate Astrocytic Functions in the Brain: Possible Therapeutic Consequences
Current Neuropharmacology subject Index To Volume 2
Current Genomics Navigating the Sea Changes in Patent Law to Successfully Build Value
Technology Transfer and Entrepreneurship (Discontinued) Connexin Modulators and Their Potential Targets under the Magnifying Glass
Current Medicinal Chemistry Quality of Life of Children with Cerebral Palsy: A Cross-Sectional KIDSCREEN study in the Southern part of the Netherlands
CNS & Neurological Disorders - Drug Targets